Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm2) From 2 Different Manufacturing Sites.
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease; Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors UCB
- 22 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 20 Aug 2009 New trial record